Combination therapies against cancer: new opportunities for transnational research
Basic Information
Despite advances in targeted therapies, immunotherapies, or radiotherapy, different obstacles, and challenges remain to be solved. Current limitations of in vitro personalized systems allowing a fast and reliable testing, new platforms to achieve combination therapy screening, new methods to achieve synergism in combination therapy and new combinations of radiotherapy with drugs or immunotherapy, remain, slowing down further applications of combination therapy in the clinic. Thus, there is a need for the identification of new and fast strategies to assay for individualized combination therapies that may help in the clinic to overcome tumour resistance and improve clinical outcomes avoiding undesired side effects. This topic should evolve from the laboratory to favour the clinical implementation of the strategies from the bench to the bedside.
Network | TRANSCAN-3 | ||||||||
Website | https://transcan.eu/funding/calls/joint-call-jtc-2024-.kl | ||||||||
Aim of the joint call | The main purpose of this call will be design of patient preclinical models for combination therapies. Translational research using tumour samples collected from retrospective and/or prospective cohorts of patients. | ||||||||
Type of joint call | Two Stages - Call with pre-proposals and full proposals submissions | ||||||||
Events |
|
||||||||
Is call co-funded? | No | ||||||||
Call follow up funding | n/a | ||||||||
Call reasons | n/a | ||||||||
Research fields |
|
||||||||
Type of research |
|
||||||||
Target groups |
|
||||||||
Participating networks | n/a |
Organisations Participating
Funded Projects
Acronym | Title | Start | End | No. partners |
---|---|---|---|---|
ACCELERATE | Functional precision medicine platform for the treatment of ... | 01/04/2026 | 31/03/2029 | 4 |
BePrepared | Building an ex vivo complex tumour microenvironment platform... | 01/04/2026 | 31/03/2029 | 5 |
DOPPLER-LC | Development Of Patient-derived organoid PLatform for Evading... | 01/04/2026 | 31/03/2029 | 5 |
GLIO-COMBO | Targeting tumor heterogeneity in pediatric high-grade gliomas | 01/04/2026 | 31/03/2029 | 4 |
HAVOC | Human avatar on chip for advancing personalized cancer thera... | 01/04/2026 | 31/03/2029 | 3 |
LUNGOIDS | Subtype-specific Lung Cancer Organoids based on artificial E... | 01/04/2026 | 31/03/2029 | 4 |
MELANOLOCK | Tackling resistance to immunotherapy in advanced melanomas t... | 01/04/2026 | 31/03/2029 | 4 |
METRICs | Metabolism/Metagenomics-based strategies for sensitization t... | 01/04/2026 | 31/03/2029 | 7 |
PREDICT-BC | Patient-derived models for the Research and Evaluation of Di... | 01/04/2026 | 31/03/2029 | 6 |
SARAH | Search for combinational therapy to target clonal haematopoi... | 01/04/2026 | 31/03/2029 | 4 |
SeqPerGlio | Intraoperative tumour sequencing for personalized loco-regio... | 01/04/2026 | 31/03/2029 | 6 |
TITAN | Novel Cancer Therapy: Inducing Double-strand DNA Breaks to F... | 01/04/2026 | 31/03/2029 | 5 |
TOSCANINI | TAD disruption and aberrant expression as leukemia metabolic... | 01/04/2026 | 31/03/2029 | 7 |
XPANTHER | Radiothermal-Driven Immune Activation to Tackle Pancreatic H... | 01/04/2026 | 31/03/2029 | 5 |
ioAVATAR | Immune oncology Drug Discovery & Decision - Advanced ex Vivo... | 01/04/2026 | 31/03/2029 | 5 |